5-FU	5-fluorouracil
AE	Adverse events
Bev	Bevacizumab
CI	Confidence interval
CI	Chemoinfusion
CRC	Colorectal cancer
CR	Complete response
CRS	Clinical risk score
CT	Computer tomography
CTR	Conversion to resection
D	Dimension
DEBIRI	Drug eluting beads loaded with Irinotecan
DFS	Disease-free survival
dMMR	Mismatch-repair deficient
ECG	Electrocardiogram
EGFR	Epidermal growth factor receptor
ESMO	European Society of Medical Oncology
FFLP	Freedom from local progression
FOLFIRI	5-fluorouracil, leucovorin, irinotecan
FOLFOX	5-fluorouracil, leucovorin, oxaliplatin
FOLFOXIRI	5-fluouracil, leucovorin, oxaliplatin, irinotecan
FUDR	Floxuridine
HCC	Hepatocellular carcinoma
HR	Hazard ratio
IL-2	Interleukin 2
IRE	Irreversible electroporation
HIFU	High-intensity focused ultrasound
LAT	Local ablative therapies
LMCRC	Liver metastases of colorectal cancer
LPFS	Local progression-free survival
LT-CoMet 21	Liver Transplantation for Colorectal liver Metastases 2021
LTP	Local tumor progression
LV	Leucovorin
mCRC	Metastatic colorectal cancer
MDT	Multidisciplinary team
mOS	Median overall survival
mPFS	Median progression-free survival
MR	Magnetic resonance
MSI	Microsatellite instability
MWA	Microwave ablation
NCCN	National Comprehensive Cancer Network
NR	Not reported
OR	Odds ratio
ORR	Overall response rate
OS	Overall survival
PFS	Progression-free survival
PVA	Polyvinyl alcohol
QT	Chemotherapy
RBOC	Radioembolization Brachytherapy Oncology Consortium
RCT	Randomized controlled trial
RE	Radioembolization
RECIST	Response evaluation criteria in solid tumors
RFA	Radiofrequency ablation
RFS	Recurrence-free survival
RILD	Radiation-induced liver disease
SBRT	Stereotactic body radiotherapy
SPRECT	Single photon emission computed tomography
TAVE	Transarterial chemoembolization
US	Ultrasound
VEGF	Vascular endothelial growth factor